News

All current DZIF news can be found here.

18 to 24 November: World Antimicrobial Awareness Week

This year again, from November 18 to 24, attention is being drawn worldwide to the threatening increase in resistance to antibiotics and other antimicrobial agents. The World Health Organisation (WHO)

Chronic hepatitis B: Development of a thermostable therapeutic vaccine

Around 300 million people are living with a chronic hepatitis B virus (HBV) infection and currently there is no cure for the disease. A team of researchers around DZIF professor Ulrike Protzer from

Prof Dirk Heinz, Prof Dirk Busch and Bettina Stark-Watzinger focus on a presentation

Federal Research Minister learns about current infection research at the HZI and DZIF

As part of her autumn tour, the Federal Minister of Education and Research, Bettina Stark-Watzinger, visited the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection

Multicentre study on extrapulmonary tuberculosis

When you hear about tuberculosis, the first thing that comes to mind is lung disease. However, almost 30 percent of tuberculosis cases in Germany affect extrapulmonary organs. The disease, triggered

Negative-stained transmission electron micrograph in black and white of round hepatitis B virus particles in white, in which internal structures are visible, against a dark background.

New study shows significant antiviral activity of the agent bulevirtide for the treatment of chronic hepatitis D virus infection

Between 10 and 20 million people worldwide are infected with hepatitis D virus (HDV). HDV infection is always associated with hepatitis B virus infection. So far there has been no satisfactory

Prof. Oliver Cornely receives Johann Lucas Schönlein Plaque from the German-speaking Mycological Society

Prof. Oliver Cornely, infectiologist and coordinator of the DZIF Clinical Trial Unit at the University Hospital Cologne, has been awarded the Johann Lucas Schönlein Plaque by the German-speaking

Left panel: grey electron microscopic image of rod-shaped M. tuberculosis bacteria; right panel: image of a circular phylogenetic tree depicting the genetic relationship between M. tuberculose strains

Personalised antibiotic treatment strategies for tuberculosis patients

Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the

Namibian mother and daughter, dressed in T-shirts and skirts, the woman additionally wearing a green-brownish-coloured headscarf, squatting in front of a light blue-coloured wall.Eine afrikanische Mutter mit Tocher, beide tragen T-Shirts und Röcke, die Mutter zudem ein grün-schwarz gemustertes gebundenes Kopftuch. Beide hocken vor einer hellblau gesprichenen Wand.

BCG tuberculosis vaccine only effective in early childhood

In the early 20th century, French scientists Albert Calmette and Camille Guérin developed a vaccine from the bovine tuberculosis bacterium Mycobacterium bovis, which was named BCG (Bacillus Calmette

Two young female scientists in a biomedical laboratory evaluating a purple-stained plaque assay in cell culture plates with 12 wells each.

RESIST: Finding new inhibitors against coronaviruses

Finding active agents against SARS-CoV-2 and other coronaviruses—this goal has been pursued by DZIF scientist Prof Thomas Schulz and his team at Hannover Medical School (MHH) since the virus first

Electron microscopic image of green-coloured MERS-coronavirus particles. Clearly visible are the spike-proteins on the surface of the virus particles that resemble a crown and give the coronavirus its name.

Booster vaccination with newly developed vaccine against MERS-CoV leads to robust long-lasting immunity

Besides SARS-CoV and SARS-CoV-2, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is among the highly pathogenic coronaviruses that can lead to severe respiratory disease and death. It is